<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>389</serviceExecutionTime><Drug id="64314"><DrugName>rosiptor acetate</DrugName><DrugNamesKey><Name id="43084539">rosiptor</Name><Name id="43084540">rosiptor acetate</Name></DrugNamesKey><DrugSynonyms><Name><Value>SHIP agonists (cancer/inflammation/COPD), Aquinox/Astellas</Value></Name><Name><Value>AQX-131</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-132</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-133</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-134</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-135</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-140</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-150</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-108</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AQX-1125</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>rosiptor</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>rosiptor acetate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>rosiptor (cancer/inflammation/COPD), Aquinox/Astellas</Value></Name><Name><Value>rosiptor acetate (cancer/inflammation/COPD), Aquinox/Astellas</Value></Name><Name><Value>rosiptor acetate (oral, bladder pain syndrome/interstitial cystitis and chronic prostatitis/chronic pelvic pain syndrome), Aquinox/Astellas</Value></Name><Name><Value>782487-29-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>782487-28-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1032979">Aquinox Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="1032979">Aquinox Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="64314" type="Drug"><TargetEntity id="675878" type="siDrug">Rosiptor acetate</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1032979" type="Company"><TargetEntity id="4296262694" type="organizationId">Aquinox Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"/><TargetEntity id="691" type="ICD9"/><TargetEntity id="10012438" type="MEDDRA"/><TargetEntity id="D003876" type="MeSH"/><TargetEntity id="-1439185598" type="omicsDisease"/><TargetEntity id="456" type="siCondition"/></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="2512" type="ciIndication"><TargetEntity id="10011796" type="MEDDRA"/><TargetEntity id="D018856" type="MeSH"/><TargetEntity id="37202" type="ORPHANET"/><TargetEntity id="-2003454252" type="omicsDisease"/><TargetEntity id="944" type="siCondition"/></SourceEntity><SourceEntity id="3000" type="ciIndication"><TargetEntity id="J32" type="ICD10"/><TargetEntity id="10009137" type="MEDDRA"/><TargetEntity id="1297" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="3916" type="ciIndication"><TargetEntity id="10005063" type="MEDDRA"/></SourceEntity><SourceEntity id="473" type="ciIndication"><TargetEntity id="N41" type="ICD10"/><TargetEntity id="10036978" type="MEDDRA"/><TargetEntity id="D011472" type="MeSH"/><TargetEntity id="-636590603" type="omicsDisease"/><TargetEntity id="363" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="708" type="ciIndication"><TargetEntity id="10037383" type="MEDDRA"/><TargetEntity id="D011658" type="MeSH"/><TargetEntity id="-439399265" type="omicsDisease"/><TargetEntity id="3975" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="50046" type="Action"><TargetEntity id="5363" type="Mechanism">Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (SHIP-1) Activators</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1102">Atopic dermatitis</Indication><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="189">Inflammatory bowel disease</Indication><Indication id="20">Pain</Indication><Indication id="2512">Interstitial cystitis</Indication><Indication id="3000">Chronic sinusitis</Indication><Indication id="31">Asthma</Indication><Indication id="3916">Bladder pain</Indication><Indication id="473">Prostatitis</Indication><Indication id="651">Cancer</Indication><Indication id="708">Pulmonary fibrosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="50046">SH2 domain inositol phosphatase 1 stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="1545">Anticancer</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-07-30T10:02:33.000Z</LastModificationDate><ChangeDateLast>2018-06-28T00:00:00.000Z</ChangeDateLast><AddedDate>2009-09-01T17:36:46.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1032979" linkType="Company"&gt;Aquinox Pharmaceuticals&lt;/ulink&gt; and  licensee &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas Pharma&lt;/ulink&gt; were  developing AQX-1125, acetate salt of rosiptor as the lead compound from oral small-molecule SH2-containing inositol 5'-phosphatase 1 (SHIP1) agonists, which also included AQX-108, -131 to -135, -140, -150 series, that inhibit the PI3K pathway, as a once-daily oral formulation, for the potential treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) [&lt;ulink linkID="1038667" linkType="Reference"&gt;1038667&lt;/ulink&gt;], [&lt;ulink linkID="1038708" linkType="Reference"&gt;1038708&lt;/ulink&gt;], [&lt;ulink linkID="1049041" linkType="Reference"&gt;1049041&lt;/ulink&gt;], [&lt;ulink linkID="1182561" linkType="Reference"&gt;1182561&lt;/ulink&gt;], [&lt;ulink linkID="1399070" linkType="Reference"&gt;1399070&lt;/ulink&gt;], [&lt;ulink linkID="1403434" linkType="Reference"&gt;1403434&lt;/ulink&gt;], [&lt;ulink linkID="1584758" linkType="Reference"&gt;1584758&lt;/ulink&gt;], [&lt;ulink linkID="2043436" linkType="Reference"&gt;2043436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, a  phase III trial (LEADERSHIP 301) was initiated for BPS/IC [&lt;ulink linkID="1788621" linkType="Reference"&gt;1788621&lt;/ulink&gt;]; in June 2018, negative data were reported; at that time, Aquinox halted further development of the drug    [&lt;ulink linkID="2049551" linkType="Reference"&gt;2049551&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Rosiptor acetate was previously being investigated for the potential treatment of cancer, pulomary fibrosis and inflammatory bowel syndrome [&lt;ulink linkID="1038667" linkType="Reference"&gt;1038667&lt;/ulink&gt;], [&lt;ulink linkID="1038708" linkType="Reference"&gt;1038708&lt;/ulink&gt;], [&lt;ulink linkID="1049041" linkType="Reference"&gt;1049041&lt;/ulink&gt;], [&lt;ulink linkID="1403434" linkType="Reference"&gt;1403434&lt;/ulink&gt;]. In September 2009,  the drug was listed as being in development for cancer [&lt;ulink linkID="1038667" linkType="Reference"&gt;1038667&lt;/ulink&gt;]. In April 2013, the drug was listed as being in phase I for pulmonary fibrosis and inflammatory bowel syndrome [&lt;ulink linkID="1403434" linkType="Reference"&gt;1403434&lt;/ulink&gt;]. In August 2014, Aquinox planned to initiate exploratory phase II trials for chronic rhinosinusitis in the second half of 2014 [&lt;ulink linkID="1584758" linkType="Reference"&gt;1584758&lt;/ulink&gt;]. However, no development for these indications has since been reported. Aquinox was also previously developing the drug for asthma, COPD and atopic dermatitis. In November 2011, a phase IIa trial for asthma was initiated [&lt;ulink linkID="1238491" linkType="Reference"&gt;1238491&lt;/ulink&gt;]; positive data were reported in May 2013 [&lt;ulink linkID="1421305" linkType="Reference"&gt;1421305&lt;/ulink&gt;]. In October 2013, a phase II trial for COPD was initiated [&lt;ulink linkID="1509778" linkType="Reference"&gt;1509778&lt;/ulink&gt;]; in July 2015, negative trial results were reported [&lt;ulink linkID="1676568" linkType="Reference"&gt;1676568&lt;/ulink&gt;]. In December 2014, a phase II trial was initiated for atopic dermatitis [&lt;ulink linkID="1623523" linkType="Reference"&gt;1623523&lt;/ulink&gt;]; in November 2015, negative data were reported [&lt;ulink linkID="1710178" linkType="Reference"&gt;1710178&lt;/ulink&gt;].  However, in March 2017, the company stated its focus would be on BPS/IC and development was presumed to be discontinued for asthma, COPD and atopic dermatitis [&lt;ulink linkID="1957098" linkType="Reference"&gt;1957098&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Aquinox holds four issued US patents, including &lt;ulink linkID="PA5623141" linkType="Patent"&gt;US-8084503&lt;/ulink&gt; and &lt;ulink linkID="PA2936758" linkType="Patent"&gt;US-7601874&lt;/ulink&gt;,  with coverage to 2024-2028 and the possibility of patent extension, and 11 foreign patents (expiry in 2024) issued in Europe, Japan, Canada, Korea, Mexico, Norway, Russia, Australia and New Zealand. The issued patents cover composition of matter  and method of use [&lt;ulink linkID="1957098" linkType="Reference"&gt;1957098&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2017, a second phase III trial was planned and would be informed by topline data from the LEADERSHIP 301 trial [&lt;ulink linkID="1957098" linkType="Reference"&gt;1957098&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2015, the company met with the Division of Bone, Reproductive and Urologic Products (DBRUP) of the US FDA. The proposed trial design for the first pivotal trial was a three-arm, randomized, double-blind, placebo controlled phase III  trial, with 12 weeks dosing followed by an open-label extension, to assess the efficacy and safety of rosiptor acetate in both male and female BPS/IC patients [&lt;ulink linkID="1726411" linkType="Reference"&gt;1726411&lt;/ulink&gt;]. In March 2016, Aquinox met with the EMA to discuss plans for development of rosiptor acetate in the treatment of patients with IC/BPS and  received feedback from the EMA including recommendations regarding proposed phase III trial design. By May 2016,   the  trial protocol had been submitted to the FDA  [&lt;ulink linkID="1760883" linkType="Reference"&gt;1760883&lt;/ulink&gt;]. In August 2016, the three-arm, multicenter, randomized, double-blind, placebo-controlled, 12-week, phase III (&lt;ulink linkID="268068" linkType="Protocol"&gt;NCT02858453&lt;/ulink&gt;; AQX-1125-301; LEADERSHIP 301) trial was expected to enroll a minimum of 300 patients with moderate-to-severe IC/BPS in the US and Europe to assess 100 and 200 mg oral doses of the drug. The primary endpoint would be the difference in the change from baseline in the maximum daily bladder pain score based on an 11-point numeric rating scale (NRS) at 12 weeks recorded by electronic diary. The trial would also include a 40-week, open-label extension [&lt;ulink linkID="1785813" linkType="Reference"&gt;1785813&lt;/ulink&gt;]. [&lt;ulink linkID="1788621" linkType="Reference"&gt;1788621&lt;/ulink&gt;]. In July 2016, the trial was initiated in the US, Europe and Canada in patients (expected n = 600)  [&lt;ulink linkID="1788621" linkType="Reference"&gt;1788621&lt;/ulink&gt;], [&lt;ulink linkID="1794074" linkType="Reference"&gt;1794074&lt;/ulink&gt;]. In March 2017, 64 patients had been enrolled [&lt;ulink linkID="1907496" linkType="Reference"&gt;1907496&lt;/ulink&gt;]. In August 2017, the company stated that the DBRUP was to  hold an Advisory Committee meeting to discuss BPS/IC [&lt;ulink linkID="1956712" linkType="Reference"&gt;1956712&lt;/ulink&gt;]; in December 2017, the DBRUP voted 15 to 0 that patients with BPS and IC should be combined in clinical trials [&lt;ulink linkID="1989902" linkType="Reference"&gt;1989902&lt;/ulink&gt;]. In February 2018, patient enrollment was completed with   410 patients enrolled  [&lt;ulink linkID="2004181" linkType="Reference"&gt;2004181&lt;/ulink&gt;]. In June 2018, data were reported from the 433 enrolled  patients, including 341 female patients, showing that the trial failed to meet its primary endpoint compared with placebo (p = 0.41) [&lt;ulink linkID="2049551" linkType="Reference"&gt;2049551&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2017, a proof-of-concept phase II trial was planned to initiate in patients with CP/CPPS. Patient enrollment was expected to commence in the first quarter of 2018 [&lt;ulink linkID="1951780" linkType="Reference"&gt;1951780&lt;/ulink&gt;]. In March 2017, the trial was expected to begin in 2Q18 [&lt;ulink linkID="2012676" linkType="Reference"&gt;2012676&lt;/ulink&gt;].   In May 2018, a 12-week, randomized, double-blind, placebo-controlled, proof-of-concept phase II  trial to evaluate the efficacy and safety of once-daily rosiptor 200 mg versus placebo in  male subjects (expected n = 100) with Chronic Prostatitis Syndrome/Chronic Pelvic Pain Syndrome (CP/CPPS) was to begin in Q2 18    in the US and Canada 	[&lt;ulink linkID="2031701" linkType="Reference"&gt;2031701&lt;/ulink&gt;]. In April 2018, the trial  (&lt;ulink linkID="336523" linkType="Protocol"&gt;NCT03500159&lt;/ulink&gt;; AQX-1125-205; ProShip) was initiated in the US and Canada. The primary endpoint was the change in maximum daily pelvic pain from baseline to week 12 versus placebo using an 11-point numeric rating scale. At that time, the trial was expected to complete in December 2019   [&lt;ulink linkID="2043874" linkType="Reference"&gt;2043874&lt;/ulink&gt;], [&lt;ulink linkID="2043436" linkType="Reference"&gt;2043436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, the company planned to initiate exploratory phase II trials for chronic rhinosinusitis with nasal polyps and atopic dermatitis in the second half of 2014 [&lt;ulink linkID="1584758" linkType="Reference"&gt;1584758&lt;/ulink&gt;]. In November 2014, the company planned to initiate atleast one of the trials before the end of 2014 with the second in the first half of 2015 [&lt;ulink linkID="1608550" linkType="Reference"&gt;1608550&lt;/ulink&gt;]. In December 2014, a randomized, double-blind, multicenter, placebo-controlled, interventional, parallel assignment phase II KINSHIP trial   (&lt;ulink linkID="218753" linkType="Protocol"&gt;NCT02324972&lt;/ulink&gt;; AQX-1125-204) was planned to be initiated in Canada to evaluate the safety and efficacy of rosiptor acetate in patients with mild-to-moderate atopic dermatitis (estimated n = 50). At that time the trial was expected to complete in March 2016 [&lt;ulink linkID="1623534" linkType="Reference"&gt;1623534&lt;/ulink&gt;]; later that month, patient dosing was initiated in the trial [&lt;ulink linkID="1623523" linkType="Reference"&gt;1623523&lt;/ulink&gt;]. In March 2015, topline results were expected by the first quarter of 2016 [&lt;ulink linkID="1642160" linkType="Reference"&gt;1642160&lt;/ulink&gt;]. In May 2015, target enrollment was completed in the trial [&lt;ulink linkID="1656216" linkType="Reference"&gt;1656216&lt;/ulink&gt;]. In November 2015, data were reported. The trial  failed to demonstrate efficacy as 200 mg qd rosiptor acetate  did not meet the primary endpoint of improvement from baseline in Total Lesion Symptom Score after 12 weeks of treatment. The drug was found to be well tolerated [&lt;ulink linkID="1710178" linkType="Reference"&gt;1710178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013,  a phase II (FLAGSHIP) trial  in patients with COPD was planned to begin in the first half of 2013  [&lt;ulink linkID="1399070" linkType="Reference"&gt;1399070&lt;/ulink&gt;]. In October 2013, a randomized, double-blind, parallel-assignment, 12-week phase II trial (&lt;ulink linkID="156772" linkType="Protocol"&gt;NCT01954628&lt;/ulink&gt;; AQX-1125-202) was initiated in the US, Australia, Denmark, Finland, Hungary, Sweden and New Zealand, in patients (expected n = 400) with COPD. The trial was expected to be initiated in January 2015. At that time, the company planned to conduct the trial in Poland  [&lt;ulink linkID="1509778" linkType="Reference"&gt;1509778&lt;/ulink&gt;].  In December 2013, the company anticipated completion of the multinational, placebo-controlled trial with the top-line results before the end of 2014 [&lt;ulink linkID="1509668" linkType="Reference"&gt;1509668&lt;/ulink&gt;]. In May 2014, top-line results were expected in the first quarter of 2015 [&lt;ulink linkID="1557613" linkType="Reference"&gt;1557613&lt;/ulink&gt;]. In November 2014, enrollment was progressing towards completion [&lt;ulink linkID="1608550" linkType="Reference"&gt;1608550&lt;/ulink&gt;]. In February 2015, enrollment in the trial was completed. At that time, the last patient final visit was anticipated  in May 2015 and topline data were expected in the near 'mid-year'   [&lt;ulink linkID="1630652" linkType="Reference"&gt;1630652&lt;/ulink&gt;]. In July 2015, 12-week data were reported showing no difference in COPD symptoms  between  rosiptor acetate and placebo treatments or secondary endpoint of medically treated exacerbations [&lt;ulink linkID="1676566" linkType="Reference"&gt;1676566&lt;/ulink&gt;]. In May 2016, clinical data were presented at the 2016 ATS International Conference in San Francisco, CA. At week12, area above EXAcerbations of Chronic pulmonary disease Tool (EXACT) score time curve was 415.4 and 391.7 for rosiptor acetate and placebo, respectively. Overall, rosiptor acetate was well tolerated [&lt;ulink linkID="1768181" linkType="Reference"&gt;1768181&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, a phase II trial  (LEADERSHIP) in patients with BPS/IC was planned to begin in the first half of 2013 [&lt;ulink linkID="1399070" linkType="Reference"&gt;1399070&lt;/ulink&gt;]. In June 2013, a randomized, double-blind, parallel-assigned, phase II trial (&lt;ulink linkID="141794" linkType="Protocol"&gt;NCT01882543&lt;/ulink&gt;; AQX-1125-201) to assess the safety and efficacy of rosiptor acetate was planned to be initiated in Canada in BPS/IC patients (expected n = 70)  later that month. At that time, the trial was expected to complete in January 2015; later that month, the trial was initiated  [&lt;ulink linkID="1444191" linkType="Reference"&gt;1444191&lt;/ulink&gt;]. In July 2013, dosing of patients was initiated and the company anticipated to complete the trial in the second half of 2014 [&lt;ulink linkID="1455571" linkType="Reference"&gt;1455571&lt;/ulink&gt;].  In May 2014, top-line results were expected in the fourth quarter of 2014 [&lt;ulink linkID="1557613" linkType="Reference"&gt;1557613&lt;/ulink&gt;]. In June 2014, the FDA accepted  the IND and at that time, the placebo-controlled trial was active in the US [&lt;ulink linkID="1564651" linkType="Reference"&gt;1564651&lt;/ulink&gt;]. In August 2014,  top-line data were expected in the  first half of 2015 [&lt;ulink linkID="1584758" linkType="Reference"&gt;1584758&lt;/ulink&gt;]. In November 2014, enrollment was progressing towards completion [&lt;ulink linkID="1608550" linkType="Reference"&gt;1608550&lt;/ulink&gt;]. In March 2015,  patient enrollment (n = 68) was completed in the multicenter trial. At that time, the last patient visit was expected in April 2015 and top-line data  were expected iin mid-2015   [&lt;ulink linkID="1637960" linkType="Reference"&gt;1637960&lt;/ulink&gt;]. In June 2015, results from the multi-center, placebo-controlled trial with 69 patients enrolled were reported. Data demonstrated that 200 mg po qd rosiptor acetate reduced mean change in pain score by 2.4 compared to 1.3 points for placebo, following six weeks of treatment but did not reach statistical significance (p = 0.061). The primary endpoint was measured on an 11-point numeric rating scale recorded by electronic diary where in approximately 49% of patients who received rosiptor acetate demonstrated a 2-point or greater reduction in pain compared to 34% of patients treated with placebo. The drug was well tolerated [&lt;ulink linkID="1673285" linkType="Reference"&gt;1673285&lt;/ulink&gt;]. In September 2015, additional data from the trial were reported at the 2015 Annual Meeting of the International Society for the Study of BPS (ESSIC) in Rome, Italy. Data demonstrated that approximately twice as many patients achieved at least a 30 and 50% reduction in pain with rosiptor acetate compared to placebo for both average and maximum daily pain [&lt;ulink linkID="1712069" linkType="Reference"&gt;1712069&lt;/ulink&gt;]. In December 2015,  Aquinox met with the FDA and shared final audited analysis of the secondary endpoint of urinary frequency from the LEADERSHIP trial demonstrating a statistically significant reduction in urinary frequency with rosiptor acetate, compared to placebo (p = 0.04) after determining that the previous unaudited analysis had not been normalized for assessing frequency over a 24 h periods. Both Aquinox and the FDA agreed that improvement in urinary frequency, in addition to reduction in pain, would be an important endpoint in assessing the benefit of rosiptor acetate to BPS/IC patients [&lt;ulink linkID="1726411" linkType="Reference"&gt;1726411&lt;/ulink&gt;]. In March 2016, further clinical data were presented at the 31st EAU Congress in Munich, Germany. rosiptor acetate showed rapid onset of action with early changes in pain. The most common TEAEs (&amp;gt; 5%) reported were dyspepsia, gastroesophageal reflux disease and sinusitis, with higher frequency in rosiptor acetate group compared with placebo [&lt;ulink linkID="1743522" linkType="Reference"&gt;1743522&lt;/ulink&gt;]. In May 2016, further clinical data were presented at the AUA Annual Meeting 2016 in San Diego, CA. The mean or geometric mean plasma concentrations for 28 and 42 days were 252 and 225 ng/ml, respectively, whereas, thte mean and geometric mean urine concentrations were 49,863 and 33,396 ng/ml, respectively (at least 40-fold higher compared with the corresponding plasma levels) [&lt;ulink linkID="1757161" linkType="Reference"&gt;1757161&lt;/ulink&gt;], [&lt;ulink linkID="1759429" linkType="Reference"&gt;1759429&lt;/ulink&gt;]. Further clinical data were presented at the same conference. In May 2016, clinical data were presented the AUA Annual Meeting 2016 in San Diego, CA. Patients treated with rosiptor acetate showed decreased e-dairy pain score (primary endpoint), maximum e-dairy score, clinic average score and maximum clinic pain score (0.4, 0.4, 0.5 and 0.6, respectively) compared with placebo (0.3, 0.4, 0.3 and 0.5, respectively). An improvement in the urinary voiding frequency and SF-12v2 scores were reported. In either of the groups there was no safety issues observed [&lt;ulink linkID="1757174" linkType="Reference"&gt;1757174&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2011, phase II studies were planned for 2012 [&lt;ulink linkID="1159237" linkType="Reference"&gt;1159237&lt;/ulink&gt;]. In November 2011, two phase IIa trials were initiated in  the UK. The first study would be  a randomized, double-blind, placebo-controlled trial to evaluate a single dose of AQX-1125 in mild and moderate asthmatic patients exposed to an allergen known to induce an asthmatic attack. The second study would be a randomized, double-blind, placebo-controlled trial to assess one of two doses of the drug in healthy volunteers exposed to an environmental inflammatory stimulus. Subjects would receive the oral drug once a day over 7 days and a key endpoint would be the reduction in inflammatory cells and markers in sputum. At that time, the trials were expected to complete in the third quarter of 2012 [&lt;ulink linkID="1238491" linkType="Reference"&gt;1238491&lt;/ulink&gt;], [&lt;ulink linkID="1255794" linkType="Reference"&gt;1255794&lt;/ulink&gt;]. In January 2012, it was reported that first-dose interim data would be available  that month, and second-dose and full analysis data would be available in June 2012 [&lt;ulink linkID="1255794" linkType="Reference"&gt;1255794&lt;/ulink&gt;]. In May 2013, data were presented from both studies at the ATS International Conference in Philadelphia, PA. In healthy volunteers, the drug inhibited the accumulation of sputum neutrophils by 67% at 24 h after inhaled lipopolysaccharide challenge. The drug also reduced sputum IL-6 levels by 67% [&lt;ulink linkID="1421405" linkType="Reference"&gt;1421405&lt;/ulink&gt;]. In patients with mild-to-moderate asthma (n = 22) rosiptor acetate inhibited the late asthmatic response (LAR), as measured by trough FEV1, with a mean difference of 180 ml between active and placebo patients. LAR AUC 4-30 was also improved in patients given rosiptor acetate, with a treatment difference of 150 ml [&lt;ulink linkID="1421305" linkType="Reference"&gt;1421305&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2013, the company listed rosiptor acetate as being in phase I for pulmonary fibrosis, inflammatory bowel syndrome and  BPS/IC [&lt;ulink linkID="1403434" linkType="Reference"&gt;1403434&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 2009, an IND was expected to be filed in 2010 [&lt;ulink linkID="1049041" linkType="Reference"&gt;1049041&lt;/ulink&gt;].   In January 2010, an IND filing was planned for December that year with clinical development expected to begin in 2011 [&lt;ulink linkID="1071680" linkType="Reference"&gt;1071680&lt;/ulink&gt;]. A phase I, single-center, double-blind, placebo-controlled, single- and multiple-ascending dose  trial began in January 2011 in 52 healthy subjects in Europe. The trial was expected to complete in the third quarter of 2011  [&lt;ulink linkID="1159237" linkType="Reference"&gt;1159237&lt;/ulink&gt;]. By November 2011, the  phase I trial conducted in three parts to assess the safety, tolerability, absorption and pharmacokinetics of rosiptor acetate had been completed. Results showed rapid absorption of the drug and also a dose-proportional pharmacokinetic profile at all doses, with a half-life of 22 h. The drug was well tolerated at all dose levels [&lt;ulink linkID="1238491" linkType="Reference"&gt;1238491&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By December 2015, Aquinox had completed a  trial that demonstrated bioequivalence between rosiptor acetate capsules and tablets. All future clinical development would utilize rosiptor acetate tablets [&lt;ulink linkID="1726411" linkType="Reference"&gt;1726411&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2016, preclinical data were presented at the AUA Annual Meeting 2016 in San Diego, CA. Visceral pain was found to be reduced by 49, 95 and 92% with the administration of 0.3, 3 and 30 mg/kg rosiptor acetate, respectively, compared with vehicle group. A significant decrease in the inflammatory parameters of bladder wall thickness and the edema score was observed with the treatment of rosiptor acetate (3 mg/kg) [&lt;ulink linkID="1756704" linkType="Reference"&gt;1756704&lt;/ulink&gt;] [&lt;ulink linkID="1759429" linkType="Reference"&gt;1759429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, preclinical data had shown that the drug exhibited the ability to reduce inflammation in the airways in response to environmental inflammatory stimuli [&lt;ulink linkID="1509668" linkType="Reference"&gt;1509668&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2013, preclinical data were presented at the ATS International Conference in Philadelphia, PA. In a 21-day prophylactic model of pulmonary fibrosis, the drug suppressed bleomycin-induced collagen deposition, inflammation and mortality. In a therapeutic model, rosiptor acetate reduced bleomycin-induced collagen airway deposition by 43 and 82% at 10 and 30 mg/kg doses respectively [&lt;ulink linkID="1421122" linkType="Reference"&gt;1421122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, preclinical data were presented at the 2011 AAAAI Annual Meeting in San Francisco, CA. In male brown Norway rats, oral administration of rosiptor acetate resulted in the inhibition of ovalbumin-induced allergic airway inflammation. Rosiptor acetate (10 mg/kg, po) was also found to inhibit ovalbumin-induced inflammatory mediator content (eotaxin, IL-1alpha and IL-11) in brown Norway rat bronchiolar lavage fluid. In female ICR, rosiptor acetate (30 mg/kg, po) inhibited phorbol 12-myristate-13-acetate induced ear edema and myeloperoxidase content of ear. In male Sprague Dawley rats, the respective Tmax, Cmax and half-life values of rosiptor acetate were 1.17 h, 1226 ng/ml and 4.5 h when administered at a dose of 30 mg/kg po  gavage, and were 0.083 h, 144 ng.ml and 5.6 h when administered at a dose of 1 mg/kg iv [&lt;ulink linkID="1182561" linkType="Reference"&gt;1182561&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2011, preclinical data were presented at the 2011 AAAAI Annual Meeting in San Francisco, CA. In vivo, rosiptor acetate (30 mg/kg) significantly decreased ear edema and myeloperoxidase content in the premenstrual asthma model. At 1 mg/kg, it significantly decreased the total leukocytes recovered in the BALF of animals sensitized and challenged with OVA, along with IL-1beta and IL-11 [&lt;ulink linkID="1180779" linkType="Reference"&gt;1180779&lt;/ulink&gt;]. In June 2011, similar data were presented at the Tenth World Congress on Inflammation in Paris, France [&lt;ulink linkID="1206267" linkType="Reference"&gt;1206267&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, preclinical data were presented at the 16th International Conference of the Inflammation Research Association (IRA) in Washington DC. In animal models of inflammation, rosiptor acetate inhibited passive cutaneous anaphylaxis, leukocyte infiltration of the lung airways and airway hyperresponsiveness (1- and 5-mg/kg doses). At a 10-mg/kg dose, rosiptor acetate inhibited inflammatory markers in rat lung tissue [&lt;ulink linkID="1131335" linkType="Reference"&gt;1131335&lt;/ulink&gt;], [&lt;ulink linkID="1135024" linkType="Reference"&gt;1135024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, preclinical data were presented at BioPartnering North America in Vancouver, Canada. Rosiptor acetate (0.3 to 30 mg/kg qd for 4 days)   led to a reduction of inflammatory leukocytes and neutrophils entering the lung in a rat lung LPS inflammation model. In a  rat ovalbumin-induced asthma model,  rosiptor acetate (0.1 to 10 mg/kg qd for 3 days (24 h lavage)) produced a dose-dependent decrease in leukocyte and eosinophil concentrations [&lt;ulink linkID="1071680" linkType="Reference"&gt;1071680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2009, rosiptor acetate had shown broad anti-inflammatory properties in preclinical studies with positive results in asthma and allergic disease models [&lt;ulink linkID="1049041" linkType="Reference"&gt;1049041&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2009,  preclinical studies were underway [&lt;ulink linkID="1038667" linkType="Reference"&gt;1038667&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ADDITONAL INFORMATION&lt;/subtitle&gt;In December 2016, , the EMA's Pediatric Committee adopted a positive opinion on a product-specific waiver recommending the obligation to submit data from clinical trials with children to be waived in all subsets of the pediatric population for rosiptor acetate for the treatment of interstitial cystitis [&lt;ulink linkID="1893809" linkType="Reference"&gt;1893809&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3916">Bladder pain</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="473">Prostatitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-06-27T00:00:00.000Z</StatusDate><Source id="2049551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2017-03-09T00:00:00.000Z</StatusDate><Source id="1957098" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-01-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2014-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="708">Pulmonary fibrosis</Indication><StatusDate>2014-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3000">Chronic sinusitis</Indication><StatusDate>2016-02-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-09-01T00:00:00.000Z</StatusDate><Source id="1038667" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2011-01-05T00:00:00.000Z</StatusDate><Source id="1159237" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2013-04-12T00:00:00.000Z</StatusDate><Source id="1403434" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2014-08-11T00:00:00.000Z</StatusDate><Source id="1584758" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2014-06-02T00:00:00.000Z</StatusDate><Source id="1564651" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2016-09-06T00:00:00.000Z</StatusDate><Source id="1794074" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2013-06-28T00:00:00.000Z</StatusDate><Source id="1444191" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2013-04-12T00:00:00.000Z</StatusDate><Source id="1403434" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="708">Pulmonary fibrosis</Indication><StatusDate>2013-04-12T00:00:00.000Z</StatusDate><Source id="1403434" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2013-06-28T00:00:00.000Z</StatusDate><Source id="1444191" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2011-03-19T00:00:00.000Z</StatusDate><Source id="1182561" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3000">Chronic sinusitis</Indication><StatusDate>2014-08-11T00:00:00.000Z</StatusDate><Source id="1584758" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2011-11-10T00:00:00.000Z</StatusDate><Source id="1238491" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2013-10-31T00:00:00.000Z</StatusDate><Source id="1509778" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2014-12-30T00:00:00.000Z</StatusDate><Source id="1623523" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2014-06-02T00:00:00.000Z</StatusDate><Source id="1564651" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2013-10-31T00:00:00.000Z</StatusDate><Source id="1509778" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2013-10-31T00:00:00.000Z</StatusDate><Source id="1509778" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2017-08-08T00:00:00.000Z</StatusDate><Source id="1951780" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2017-08-08T00:00:00.000Z</StatusDate><Source id="1951780" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-04-18T00:00:00.000Z</StatusDate><Source id="2043874" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2512">Interstitial cystitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-05-09T00:00:00.000Z</StatusDate><Source id="2032344" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2018-04-18T00:00:00.000Z</StatusDate><Source id="2043874" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-04-18T00:00:00.000Z</StatusDate><Source id="2043874" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-04-18T00:00:00.000Z</StatusDate><Source id="2043874" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3916">Bladder pain</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="1788621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-09-01T00:00:00.000Z</StatusDate><Source id="1038667" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-09036"><Name>SH2 domain inositol phosphatase 1</Name><SwissprotNumbers><Swissprot>P97573</Swissprot><Swissprot>Q6P4S2</Swissprot><Swissprot>Q92835</Swissprot><Swissprot>Q9ES52</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1032979">Aquinox Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="27664">Orexo AB</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(=O)O.C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C</Smiles><Smiles>C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C</Smiles></StructureSmiles><Deals><Deal id="149863" title="Biolipox to acquire Aquinox Pharmaceuticals' AQX-1125 assets  "/><Deal id="246884" title="Astellas to develop and commercialize Aquinox's rosiptor for IC/BPS in worldwide, Asia-Pacific region including Japan and ex-China and India"/></Deals><PatentFamilies><PatentFamily id="3489757" number="WO-2016210146" title="Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5R,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol"/><PatentFamily id="3726629" number="WO-2017127753" title="Synthesis of a substituted indene derivative"/><PatentFamily id="3997275" number="WO-2018058144" title="SHIP1 activator for treating prostatis"/><PatentFamily id="4113688" number="WO-2018126040" title="Crystalline solid forms of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol"/><PatentFamily id="622958" number="WO-2004092100" title="Indene derivatives as pharmaceutical agents"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aquinox Pharmaceuticals Inc" id="1032979"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Inflazyme Pharmaceuticals" id="17219"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>